

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 May 2007 (18.05.2007)

PCT

(10) International Publication Number
WO 2007/054579 A1

(51) International Patent Classification:

A61K 31/553 (2006.01) A61P 35/00 (2006.01)
A61K 31/4025 (2006.01)

Steinwiesstrasse 75, CH-8032 Zurich (CH). **NIGGLI, Felix, K.** [CH/CH]; University Children's Hospital, Department Oncology, Steinwiesstrasse 75, CH-8032 Zurich (CH).

(21) International Application Number:

PCT/EP2006/068410

(74) Agent: **ROTH, Peter, R.**; NOVARTIS, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:

13 November 2006 (13.11.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/736,222 14 November 2005 (14.11.2005) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicants (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **NOVARTIS PHARMA GmbH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FABBRO, Dori-ano** [CH/CH]; Im Lee 54, CH-4144 Arlesheim (CH). **WACHTEL, Marco** [CH/CH]; University Children's Hospital, Department Oncology, Steinwiesstrasse 75, CH-8032 Zurich (CH). **SCHAFER, Beat, W.** [CH/CH]; University Children's Hospital, Department Oncology, Steinwiesstrasse 75, CH-8032 Zurich (CH). **AMSTUTZ, Ralf** [CH/CH]; University Children's Hospital, Department Oncology, Steinwiesstrasse 75, CH-8032 Zurich (CH). **TROXLER, Heinz** [CH/CH]; University Children's Hospital, Department Oncology, Steinwiesstrasse 75, CH-8032 Zurich (CH). **KLEINERT, Peter** [CH/CH]; University Children's Hospital, Department Oncology,

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STAUROSPORINE DERIVATIVES FOR USE IN ALVEOLAR RHABDOMYOSARCOMA

(57) Abstract: This invention relates to staurosporine derivatives are effective when used in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation including a PAX3/FKHR translocation and a PAX7/FKHR translocation, more especially a solid tumor disease such as a Sarcoma, most especially an Alveolar Rhabdomyosarcoma.


WO 2007/054579 A1

STAUROSPOURINE DERIVATIVES FOR USE IN ALVEOLAR RHABDOMYOSARCOMA

[001] This invention relates to organic compounds, in particular to pharmaceutical compositions for use for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation, especially a Sarcoma, especially Alveolar Rhabdomyosarcoma.


[002] We have now found that certain the FLT-3 inhibitors, especially staurosporine derivatives, are effective when used in the treatment of a disease associated with a PAX/FKHR translocation, especially of a disease associated with PAX/FKHR expression, most especially of Pediatric sarcoma alveolar rhabdomyosarcoma ("aRMS"). In one embodiment, aRMS expresses the chimaeric fusion protein PAX3/FKHR due to a chromosomal translocation event t(2;13). In another embodiment, aRMS expresses the chimaeric fusion protein PAX7/FKHR due to a chromosomal translocation event t(1;13). See Mendelian Inheritance in Man accno. #268220.

[003] Accordingly the invention provides a method for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation, especially a Sarcoma, more especially a Alveolar Rhabdomyosarcoma, in a subject in need of such treatment, wherein such treatment comprises administering to the subject an effective amount of a staurosporine derivatives of formula




[004] wherein (II) is the partially hydrogenated derivative of compound (I),


- 2 -




or



or



or



or

[005] wherein R_1 and R_2 , are, independently of one another, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

[006] n and m are, independently of one another, a number from and including 0 to and including 4;

[007] n' and m' are, independently of one another, a number from and including 0 to and including 4;

[008] R_3 , R_4 , R_8 and R_{10} are, independently of one another, hydrogen, $-O^-$, acyl with up to 30 carbon atoms, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, an acyl with up to 30 carbon atoms, wherein R_4 may also be absent;

[009] or if R_3 is acyl with up to 30 carbon atoms, R_4 is not an acyl;

- 3 -

[0010] p is 0 if R₄ is absent, or is 1 if R₃ and R₄ are both present and in each case are one of the aforementioned radicals;

[0011] R₅ is hydrogen, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms;

[0012] R₇, R₆ and R₉ are acyl or –(lower alkyl)–acyl, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, carbonyl, carbonyldioxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

[0013] X stands for 2 hydrogen atoms; for 1 hydrogen atom and hydroxy; for O; or for hydrogen and lower alkoxy;

[0014] Z stands for hydrogen or lower alkyl;

[0015] and either the two bonds characterised by wavy lines are absent in ring A and replaced by 4 hydrogen atoms, and the two wavy lines in ring B each, together with the respective parallel bond, signify a double bond;

[0016] or the two bonds characterised by wavy lines are absent in ring B and replaced by a total of 4 hydrogen atoms, and the two wavy lines in ring A each, together with the respective parallel bond, signify a double bond;

[0017] or both in ring A and in ring B all of the 4 wavy bonds are absent and are replaced by a total of 8 hydrogen atoms;

[0018] or a salt thereof, if at least one salt-forming group is present.

[0019] The general terms and definitions used hereinbefore and hereinafter preferably have the following meanings for the staurosporine derivatives:

[0020] The prefix “lower” indicates that the associated radical preferably has up to and including a maximum of 7 carbon atoms, especially up to and including a maximum of 4 carbon atoms.

[0021] Lower alkyl is especially methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, and also pentyl, hexyl, or heptyl.

- 4 -

[0022] Unsubstituted or substituted alkyl is preferably C₁-C₂₀alkyl, especially lower alkyl, typically methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, which is unsubstituted or substituted especially by halogen, such as fluorine, chlorine, bromine, or iodine, C₆-C₁₄aryl, such as phenyl or naphthyl, hydroxy, etherified hydroxy, such as lower alkoxy, phenyl-lower alkoxy or phenyloxy, esterified hydroxy, such as lower alkanoyloxy or benzoyloxy, amino, mono- or disubstituted amino, such as lower alkylamino, lower alkanoylamino, phenyl-lower alkylamino, N,N-di-lower alkylamino, N,N-di-(phenyl-lower alkyl)amino, cyano, mercapto, substituted mercapto, such as lower alkylthio, carboxy, esterified carboxy, such as lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, such as N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, sulfo, substituted sulfo, such as lower alkanesulfonyl or lower alkoxysulfonyl, aminosulfonyl or N-mono- or N,N-disubstituted aminosulfonyl, such as N-lower alkylaminosulfonyl or N,N-di-lower alkylaminosulfonyl.

[0023] Halogen is preferably fluorine, chlorine, bromine, or iodine, especially fluorine or chlorine.

[0024] Etherified hydroxy is especially lower alkoxy, C₆-C₁₄aryloxy, such as phenyloxy, or C₆-C₁₄aryl-lower alkoxy, such as benzyloxy.

[0025] Esterified hydroxy is preferably lower alkanoyloxy or C₆-C₁₄arylcarbonyloxy, such as benzoyloxy.

[0026] Mono- or disubstituted amino is especially amino monosubstituted or disubstituted by lower alkyl, C₆-C₁₄aryl, C₆-C₁₄aryl-lower alkyl, lower alkanoyl, or C₆-C₁₂arylcarbonyl.

[0027] Substituted mercapto is especially lower alkylthio, C₆-C₁₄arylthio, C₆-C₁₄aryl-lower alkylthio, lower alkanoylthio, or C₆-C₁₄aryl-lower alkanoylthio.

[0028] Esterified carboxy is especially lower alkoxycarbonyl, C₆-C₁₄aryl-lower alkoxy-carbonyl or C₆-C₁₄aryloxycarbonyl.

[0029] N-Mono- or N,N-disubstituted carbamoyl is especially carbamoyl N-monosubstituted or N,N-disubstituted by lower alkyl, C₆-C₁₄aryl or C₆-C₁₄aryl-lower alkyl.

[0030] Substituted sulfonyl is especially C₆-C₁₄arylsulfonyl, such as toluenesulfonyl, C₆-C₁₄aryl-lower alkanesulfonyl or lower alkanesulfonyl.

[0031] N-Mono- or N,N-disubstituted aminosulfonyl is especially aminosulfonyl N-monosubstituted or N,N-disubstituted by lower alkyl, C₆-C₁₄aryl or C₆-C₁₄aryl-lower alkyl.

[0032] C₆-C₁₄Aryl is an aryl radical with 6 to 14 carbon atoms in the ring system, such as phenyl, naphthyl, fluorenyl, or indenyl, which is unsubstituted or is substituted especially by halogen, such as fluorine, chlorine, bromine, or iodine, phenyl or naphthyl, hydroxy, lower alkoxy, phenyl-lower alkoxy, phenyloxy, lower alkanoyloxy, benzoyloxy, amino, lower alkylamino, lower alkanoylamino, phenyl-lower alkylamino, N,N-di-lower alkylamino, N,N-di-(phenyl-lower alkyl)amino, cyano, mercapto, lower alkylthio, carboxy, lower alkoxy-carbonyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl, sulfo, lower alkanesulfonyl, lower alkoxy-sulfonyl, aminosulfonyl, N-lower alkylaminosulfonyl, or N,N-di-lower alkylamino-sulfonyl.

[0033] The indices n and m are in each case preferably 1, 2 or especially 0. In general, compounds of formula I in which n and m are in each case 0 (zero) are especially preferred.

[0034] An aliphatic carbohydrate radical R₃, R₄, R₈ or R₁₀ with up to 29 carbon atoms, which is substituted by acyclic substituents and preferably has a maximum of 18, especially a maximum of 12, and as a rule not more than 7 carbon atoms, may be saturated or unsaturated and is especially an unsubstituted or a straight-chain or branched lower alkyl, lower alkenyl, lower alkadienyl, or lower alkynyl radical substituted by acyclic substituents. Lower alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and also n-pentyl, isopentyl, n-hexyl, isohexyl and n-heptyl; lower alkenyl is, for example, allyl, propenyl, isopropenyl, 2- or 3-methyl and 2- or 3-butenyl; lower alkadienyl is, for example, 1-penta-2,4-dienyl; lower alkynyl is, for example, propargyl or 2-butylnyl. In corresponding unsaturated radicals, the double bond is especially located in a position higher than the α -position in relation to the free valency. Substituents are especially the acyl radicals defined hereinbelow as substituents of R^o, preferably free or esterified carboxy, such as carboxy or lower alkoxy-carbonyl, cyano or di-lower alkylamino.

[0035] A carbocyclic or carbocyclic-aliphatic radical R₃, R₄, R₈ or R₁₀ with up to 29 carbon atoms in each case is especially an aromatic, a cycloaliphatic, a cycloaliphatic-aliphatic, or an aromatic-aliphatic radical which is either present in unsubstituted form or substituted by radicals referred to hereinbelow as substituents of R^o. An aromatic radical (aryl radical) R₃ or R₄ is most especially a phenyl, also a naphthyl, such as 1- or 2-naphthyl, a biphenyl, such as especially 4-biphenyl, and also an anthryl, fluorenyl and azuleny, as well as their aromatic analogues with one or more saturated rings, which is either present in unsubstituted form or substituted by radicals referred to hereinbelow as substituents of R^o. Preferred aromatic-aliphatic radicals are aryl-lower alkyl- and aryl-lower alkenyl radicals, e.g. phenyl-

lower alkyl or phenyl-lower alkenyl with a terminal phenyl radical, such as for example benzyl, phenethyl, 1-, 2-, or 3-phenylpropyl, diphenylmethyl (benzhydryl), trityl, and cinnamyl, and also 1- or 2-naphthylmethyl. Of aryl radicals carrying acyclic radicals, such as lower alkyl, special mention is made of o-, m- and p-tolyl and xylyl radicals with variously situated methyl radicals.

[0036] A cycloaliphatic radical R_3 , R_4 , R_8 or R_{10} with up to 29 carbon atoms is especially a substituted or preferably unsubstituted mono-, bi-, or polycyclic cycloalkyl-, cycloalkenyl-, or cycloalkadienyl radical. Preference is for radicals with a maximum of 14, especially 12, ring-carbon atoms and 3- to 8-, preferably 5- to 7-, and most especially 6-member rings which can also carry one or more, for example two, aliphatic hydrocarbon radicals, for example those named above, especially the lower alkyl radicals, or other cycloaliphatic radicals as substituents. Preferred substituents are the acyclic substituents named hereinbelow for R° .

[0037] A cycloaliphatic-aliphatic radical R_3 , R_4 , R_8 or R_{10} with up to 29 carbon atoms is a radical in which an acyclic radical, especially one with a maximum of 7, preferably a maximum of 4 carbon atoms, such as especially methyl, ethyl, and vinyl, carries one or more cycloaliphatic radicals as defined hereinabove. Special mention is made of cycloalkyl-lower -alkyl radicals, as well as their analogues which are unsaturated in the ring and/or in the chain, but are non-aromatic, and which carry the ring at the terminal carbon atom of the chain. Preferred substituents are the acyclic substituents named herein below for R° .

[0038] Heterocyclic radicals R_3 , R_4 , R_8 or R_{10} with up to 20 carbon atoms each and up to 9 heteroatoms each are especially monocyclic, but also bi- or polycyclic, aza-, thia-, oxa-, thiaza-, oxaza-, diaza-, triaza-, or tetrazacyclic radicals of an aromatic character, as well as corresponding heterocyclic radicals of this type which are partly or most especially wholly saturated, these radicals – if need be – possibly carrying further acyclic, carbocyclic, or heterocyclic radicals and/or possibly mono-, di-, or polysubstituted by functional groups, preferably those named hereinabove as substituents of aliphatic hydrocarbon radicals. Most especially they are unsubstituted or substituted monocyclic radicals with a nitrogen, oxygen, or sulfur atom, such as 2-aziridinyl, and especially aromatic radicals of this type, such as pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3-, or 4-pyridyl, and also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl; analogous bicyclic radicals with an oxygen, sulfur, or nitrogen atom are, for example, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, or benzothienyl, typically 2- or 3-benzothienyl; preferred monocyclic and bicyclic radicals with several heteroatoms are, for

- 7 -

example, imidazolyl, typically 2- or 4-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, or thiazolyl, typically 2-thiazolyl, and benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, or quinazolyl, typically 2-quinazolinyl. Appropriate partially or, especially, completely saturated analogous radicals may also be considered, such as 2-tetrahydrofuryl, 2- or 3-pyrrolidinyl, 2-, 3-, or 4-piperidyl, and also 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl and N-mono- or N,N'-bis-lower alkyl-2-piperazinyl radicals. These radicals may also carry one or more acyclic, carbocyclic, or heterocyclic radicals, especially those mentioned hereinabove. The free valency of the heterocyclic radicals R_3 or R_4 must emanate from one of their carbon atoms. Heterocyclyl may be unsubstituted or substituted by one or more, preferably one or two, of the substituents named hereinbelow for R° .

[0039] Heterocyclic-aliphatic radicals R_3 , R_4 , R_8 or R_{10} especially lower alkyl radicals, especially with a maximum of 7, preferably a maximum of 4 carbon atoms, for example those named hereinabove, which carry one, two, or more heterocyclic radicals, for example those named in the preceding paragraph, the heterocyclic ring possibly being linked to the aliphatic chain also by one of its nitrogen atoms. A preferred heterocyclic-aliphatic radical R_1 is, for example, imidazol-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, piperazin-1-ylmethyl, 2-(morpholin-4-yl)ethyl and also pyrid-3-ylmethyl. Heterocyclyl may be unsubstituted or substituted by one or more, preferably one or two, of the substituents named hereinbelow for R° .

[0040] A heteroaliphatic radical R_3 , R_4 , R_8 or R_{10} with up to 20 carbon atoms each and up to 10 heteroatoms each is an aliphatic radical which, instead of one, two, or more carbon atoms, contains identical or different heteroatoms, such as especially oxygen, sulfur, and nitrogen. An especially preferred arrangement of a heteroaliphatic radical R_1 takes the form of oxa-alkyl radicals in which one or more carbon atoms are replaced in a preferably linear alkyl by oxygen atoms preferably separated from one another by several (especially 2) carbon atoms so that they form a repeating group, if need be multi-repeating group $(O-CH_2-CH_2)_q$, wherein $q = 1$ to 7.

[0041] Especially preferred as R_3 , R_4 , R_8 or R_{10} , apart from acyl, is lower alkyl, particularly methyl or ethyl; lower alkoxycarbonyl-lower alkyl, especially methoxycarbonylmethyl or 2-(tert-butoxycarbonyl)ethyl; carboxy-lower alkyl, especially carboxymethyl or 2-carboxyethyl; or cyano-lower alkyl, especially 2-cyanoethyl.

[0042] An acyl radical R_3 , R_4 , R_6 , R_7 , R_8 , R_9 , or R_{10} with up to 30 carbon atoms derives from a carboxylic acid, functionally modified if need be, an organic sulfonic acid, or a phosphoric acid, such as pyro- or orthophosphoric acid, esterified if need be.

[0043] An acyl designated Ac^1 and derived from a carboxylic acid, functionally modified if need be, is especially one of the subformula $Y-C(=W)-$, wherein W is oxygen, sulfur, or imino and Y is hydrogen, hydrocarbyl R° with up to 29 carbon atoms, hydrocarbyloxy $R^\circ-O-$, an amino group or a substituted amino group, especially one of the formula $R^\circ HN-$ or $R^\circ R^\circ N-$ (wherein the R° radicals may be identical or different from one another).

[0044] The hydrocarbyl (hydrocarbon radical) R° is an acyclic (aliphatic), carbocyclic, or carbocyclic-acyclic hydrocarbon radical, with up to 29 carbon atoms each, especially up to 18, and preferably up to 12 carbon atoms, and is saturated or unsaturated, unsubstituted or substituted. Instead of one, two, or more carbon atoms, it may contain identical or different heteroatoms, such as especially oxygen, sulfur, and nitrogen in the acyclic and/or cyclic part; in the latter case, it is described as a heterocyclic radical (heterocyclyl radical) or a hetero-cyclic-acyclic radical.

[0045] Unsaturated radicals are those, which contain one or more, especially conjugated and/or isolated, multiple bonds (double or triple bonds). The term cyclic radicals includes also aromatic and non-aromatic radicals with conjugated double bonds, for example those wherein at least one 6-member carbocyclic or a 5- to 8-member heterocyclic ring contains the maximum number of non-cumulative double bonds. Carbocyclic radicals, wherein at least one ring is present as a 6-member aromatic ring (i.e. a benzene ring), are defined as aryl radicals.

[0046] An acyclic unsubstituted hydrocarbon radical R° is especially a straight-chained or branched lower alkyl-, lower alkenyl-, lower alkadienyl-, or lower alkynyl radical. Lower alkyl R° is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and also n-pentyl, isopentyl, n-hexyl, isohexyl and n-heptyl; lower alkenyl is, for example, allyl, propenyl, isopropenyl, 2- or 3-methallyl and 2- or 3-butenyl; lower alkadienyl is, for example, 1-penta-2,4-dienyl; lower alkynyl is, for example, propargyl or 2-butenyl. In corresponding unsaturated radicals, the double bond is especially located in a position higher than the α -position in relation to the free valency.

[0047] A carbocyclic hydrocarbon radical R° is especially a mono-, bi-, or polycyclic cycloalkyl-, cycloalkenyl-, or cycloalkadienyl radical, or a corresponding aryl radical. Preference is for radicals with a maximum of 14, especially 12, ring-carbon atoms and 3- to

8-, preferably 5- to 7-, and most especially 6-member rings which can also carry one or more, for example two, acyclic radicals, for example those named above, especially the lower alkyl radicals, or other carbocyclic radicals. Carbocyclic-acyclic radicals are those in which an acyclic radical, especially one with a maximum of 7, preferably a maximum of 4 carbon atoms, such as especially methyl, ethyl and vinyl, carries one or more carbocyclic, if need be aromatic radicals of the above definition. Special mention is made of cycloalkyl-lower and aryl-lower alkyl radicals, as well as their analogues which are unsaturated in the ring and/or chain, and which carry the ring at the terminal carbon atom of the chain.

[0048] Cycloalkyl R° has most especially from 3 up to and including 10 carbon atoms and is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, as well as bicyclo[2,2,2]octyl, 2-bicyclo[2,2,1]heptyl, and adamantyl, which may also be substituted by 1, 2, or more, for example lower, alkyl radicals, especially methyl radicals; cycloalkenyl is for example one of the monocyclic cycloalkyl radicals already named which carries a double bond in the 1-, 2-, or 3 position. Cycloalkyl-lower alkyl or -lower alkenyl is for example a -methyl, -1- or -2-ethyl, -1- or -2-vinyl, -1-, -2-, or -3-propyl or -allyl substituted by one of the above-named cycloalkyl radicals, those substituted at the end of the linear chain being preferred.

[0049] An aryl radical R° is most especially a phenyl, also a naphthyl, such as 1- or 2-naphthyl, a biphenyl, such as especially 4-biphenyl, and also an anthryl, fluorenyl and azuleny, as well as their aromatic analogues with one or more saturated rings. Preferred aryl-lower alkyl and -lower alkenyl radicals are, for example, phenyl-lower alkyl or phenyl-lower alkenyl with a terminal phenyl radical, such as for example benzyl, phenethyl, 1-, 2-, or 3-phenylpropyl, diphenylmethyl (benzhydryl), trityl, and cinnamyl, and also 1- or 2-naphthyl-methyl. Aryl may be unsubstituted or substituted.

[0050] Heterocyclic radicals, including heterocyclic-acyclic radicals, are especially monocyclic, but also bi- or polycyclic, aza-, thia-, oxa-, thiaza-, oxaza-, diaza-, triaza-, or tetrazacyclic radicals of an aromatic character, as well as corresponding heterocyclic radicals of this type which are partly or most especially wholly saturated; if need be, for example as in the case of the above-mentioned carbocyclic or aryl radicals, these radicals may carry further acyclic, carbocyclic, or heterocyclic radicals and/or may be mono-, di-, or polysubstituted by functional groups. The acyclic part in heterocyclic-acyclic radicals has for example the meaning indicated for the corresponding carbocyclic-acyclic radicals. Most especially they are unsubstituted or substituted monocyclic radicals with a nitrogen, oxygen, or sulfur atom, such as 2-aziridinyl, and especially aromatic radicals of this type, such as pyrrolyl, for

- 10 -

example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3-, or 4-pyridyl, and also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl; analogous bicyclic radicals with an oxygen, sulfur, or nitrogen atom are, for example, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, or benzothienyl, typically 2- or 3-benzothienyl; preferred monocyclic and bicyclic radicals with several heteroatoms are, for example, imidazolyl, typically 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, or thiazolyl, typically 2-thiazolyl, and benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, or quinazolyl, typically 2-quinazolyl. Appropriate partially or, especially, completely saturated analogous radicals may also be considered, such as 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 3-pyrrolidyl, 2-, 3-, or 4-piperidyl, and also 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl, and N,N'-bis-lower alkyl-2-piperazinyl radicals. These radicals may also carry one or more acyclic, carbocyclic, or heterocyclic radicals, especially those mentioned hereinabove. Heterocyclic-acyclic radicals are especially derived from acyclic radicals with a maximum of 7, preferably a maximum of 4 carbon atoms, for example those named hereinabove, and may carry one, two, or more heterocyclic radicals, for example those named hereinabove, the ring possibly being linked to the aliphatic chain also by one of its nitrogen atoms.

[0051] As already mentioned, a hydrocarbyl (including a heterocyclyl) may be substituted by one, two, or more identical or different substituents (functional groups); one or more of the following substituents may be considered: lower alkyl; free, etherified and esterified hydroxyl groups; carboxy groups and esterified carboxy groups; mercapto- and lower alkylthio- and, if need be, substituted phenylthio groups; halogen atoms, typically chlorine and fluorine, but also bromine and iodine; *halogen-lower alkyl groups*; oxo groups which are present in the form of formyl (i.e. aldehydo) and keto groups, also as corresponding acetals or ketals; azido groups; nitro groups; cyano groups; primary, secondary and preferably tertiary amino groups, amino-lower alkyl, mono- or disubstituted amino-lower alkyl, primary or secondary amino groups protected by conventional protecting groups (especially lower alkoxy carbonyl, typically tert-butoxycarbonyl) lower alkylendioxy, and also free or functionally modified sulfo groups, typically sulfamoyl or sulfo groups present in free form or as salts. The hydrocarbyl radical may also carry carbamoyl, ureido, or guanidino groups, which are free or which carry one or two substituents, and cyano groups. The above use of the word "groups" is taken to imply also an individual group.

- 11 -

[0052] Halogen-lower alkyl contains preferably 1 to 3 halogen atoms; preferred is trifluoromethyl or chloromethyl.

[0053] An etherified hydroxyl group present in the hydrocarbyl as substituent is, for example, a lower alkoxy group, typically the methoxy-, ethoxy-, propoxy-, isopropoxy-, butoxy-, and tert-butoxy group, which may also be substituted, especially by (i) heterocyclyl, whereby heterocyclyl can have preferably 4 to 12 ring atoms, may be unsaturated, or partially or wholly saturated, is mono- or bicyclic, and may contain up to three heteroatoms selected from nitrogen, oxygen, and sulfur, and is most especially pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3- or 4-pyridyl, and also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, benzothienyl, typically 2- or 3-benzothienyl; imidazolyl, typically 1- or 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, thiazolyl, typically 2-thiazolyl, benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, quinazolyl, typically 2-quinazolinyl, 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidyl, 1-, 2-, 3-, or 4-piperidyl, 1-, 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl or N,N'-bis-lower alkyl-2-piperazinyl; and also (ii) by halogen atoms, for example mono-, di-, or polysubstituted especially in the 2-position, as in the 2,2,2-trichloroethoxy, 2-chloroethoxy, or 2-iodoethoxy radical, or (iii) by hydroxy or (iv) lower alkoxy radicals, each preferably monosubstituted, especially in the 2-position, as in the 2-methoxyethoxy radical. Such etherified hydroxyl groups are also unsubstituted or substituted phenoxy radicals and phenyl-lower alkoxy radicals, such as especially benzyloxy, benzhydryloxy, and triphenylmethoxy (trityloxy), as well as heterocyclyloxy radicals, wherein heterocyclyl can have preferably 4 to 12 ring atoms, may be unsaturated, or partially or wholly saturated, is mono- or bicyclic, and may contain up to three heteroatoms selected from nitrogen, oxygen, and sulfur, and is most especially pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3- or 4-pyridyl, and also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, benzothienyl, typically 2- or 3-benzothienyl; imidazolyl, typically 1- or 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, thiazolyl, typically 2-thiazolyl, benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, quinazolyl, typically 2-quinazolinyl, 2-tetrahydrofuryl, 4-

- 12 -

tetrahydrofuryl, 2- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidyl, 1-, 2-, 3-, or 4-piperidyl, 1-, 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl or N,N'-bis-lower alkyl-2-piperazinyl; such as especially 2- or 4-tetrahydropyranyloxy.

[0054] Etherified hydroxyl groups in this context are taken to include silylated hydroxyl - groups, typically for example tri-lower alkylsilyloxy, typically trimethylsilyloxy and dimethyl-tert-butylsilyloxy, or phenyldi-lower alkylsilyloxy and lower alkyl-diphenylsilyloxy.

[0055] An esterified hydroxyl group present in the hydrocarbyl as a substituent is, for example, lower alkanoyloxy.

[0056] A carboxyl group present in the hydrocarbyl as a substituent is one in which the hydrogen atom is replaced by one of the hydrocarbyl radicals characterised hereinabove, preferably a lower alkyl- or phenyl-lower alkyl radical; an example of an esterified carboxyl group is lower alkoxycarbonyl or phenyl-lower alkoxycarbonyl substituted if need be in the phenyl part, especially the methoxy, ethoxy, tert-butoxy, and benzyloxycarbonyl group, as well as a lactonised carboxyl group.

[0057] A primary amino group $-NH_2$ as substituent of the hydrocarbyls may also be present in a form protected by a conventional protecting group. A secondary amino group carries, instead of one of the two hydrogen atoms, a hydrocarbyl radical, preferably an unsubstituted one, typically one of the above-named, especially lower alkyl, and may also be present in protected form.

[0058] A tertiary amino group present in the hydrocarbyl as substituent carries 2 different or, preferably, identical hydrocarbyl radicals (including the heterocyclic radicals), such as the unsubstituted hydrocarbyl radicals characterised hereinabove, especially lower alkyl.

[0059] A preferred amino group is one with the formula $R_{11}(R_{12})N-$, wherein R_{11} and R_{12} are independently in each case hydrogen, unsubstituted acyclic C_1 - C_7 -hydrocarbyl (such as especially C_1 - C_4 alkyl or C_2 - C_4 alkenyl) or monocyclic aryl, aralkyl, or aralkenyl, substituted if necessary by C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, halogen, and/or nitro, and having a maximum of 10 carbon atoms, where the carbon-containing radicals may be interlinked through a carbon-carbon bond or an oxygen atom, a sulfur atom, or a nitrogen atom substituted if necessary by hydrocarbyl. In such a case, they form a nitrogen-containing heterocyclic ring with the nitrogen atom of the amino group. The following are examples of especially preferred disubstituted amino groups: di-lower alkylamino, typically dimethylamino or diethylamino, pyrrolidino, imidazol-1-yl, piperidino, piperazino, 4-lower alkylpiperazino, morpholino, thiomorpholino and piperazino or 4-methylpiperazino, as well as diphenylamino and

- 13 -

dibenzylamino substituted if need be, especially in the phenyl part, for example by lower-alkyl, lower-alkoxy, halogen, and/or nitro; of the protected groups, especially lower alkoxy-carbonylamino, typically tert-butoxycarbonylamino, phenyl-lower alkoxy-carbonylamino, typically 4-methoxybenzyloxycarbonylamino, and 9-fluorenylmethoxycarbonylamino.

[0060] Amino-lower alkyl is most especially substituted in the 1-position of the lower alkyl chain by amino and is especially aminomethyl.

[0061] Mono- or disubstituted amino-lower alkyl is amino-lower alkyl substituted by one or two radicals, wherein amino-lower alkyl is most especially substituted by amino in the 1-position of the lower alkyl chain and is especially aminomethyl; the amino substituents here are preferably (if 2 substituents are present in the respective amino group independently of one another) from the group comprising lower alkyl, such as especially methyl, ethyl or n-propyl, hydroxy-lower alkyl, typically 2-hydroxyethyl, C₃-C₈cycloalkyl, especially cyclohexyl, amino-lower alkyl, typically 3-aminopropyl or 4-aminobutyl, N-mono- or N,N-di(lower alkyl)-amino-lower alkyl, typically 3-(N,N-dimethylamino)propyl, amino, N-mono- or N,N-di-lower alkylamino and N-mono- or N,N-di-(hydroxy-lower alkyl)amino.

[0062] Disubstituted amino-lower alkyl is also a 5 or 6-membered, saturated or unsaturated heterocyclyl bonded to lower alkyl via a nitrogen atom (preferably in the 1-position) and having 0 to 2, especially 0 or 1, other heteroatoms selected from oxygen, nitrogen, and sulfur, which is unsubstituted or substituted, especially by one or two radicals from the group comprising lower alkyl, typically methyl, and also oxo. Preferred here is pyrrolidino (1-pyrrolidinyl), piperidino (1-piperidinyl), piperazino (1-piperazinyl), 4-lower alkylpiperazino, typically 4-methylpiperazino, imidazolino (1-imidazolyl), morpholino (4-morpholinyl), or also thiomorpholino, S-oxo-thiomorpholino, or S,S-dioxothiomorpholino.

[0063] Lower alkylenedioxy is especially methylenedioxy.

[0064] A carbamoyl group carrying one or two substituents is especially aminocarbonyl (carbamoyl) which is substituted by one or two radicals at the nitrogen; the amino substituents here are preferably (if 2 substituents are present in the respective amino group independently of one another) from the group comprising lower alkyl, such as especially methyl, ethyl or n-propyl, hydroxy-lower alkyl, typically 2-hydroxyethyl, C₃-C₈cycloalkyl, especially cyclohexyl, amino-lower alkyl, typically 3-aminopropyl or 4-aminobutyl, N-mono- or N,N-di(lower alkyl)-amino-lower alkyl, typically 3-(N,N-dimethylamino)propyl, amino, N-mono- or N,N-di-lower alkylamino and N-mono- or N,N-di-(hydroxy-lower alkyl)amino; disubstituted amino in aminocarbamoyl is also a 5 or 6-membered, saturated or unsaturated heterocyclyl

- 14 -

with a bonding nitrogen atom and 0 to 2, especially 0 or 1, other heteroatoms selected from oxygen, nitrogen, and sulfur, which is unsubstituted or substituted, especially by one or two radicals from the group comprising lower alkyl, typically methyl, and also oxo. Preferred here is pyrrolidino (1-pyrrolidinyl), piperidino (1-piperidinyl), piperazino (1-piperazinyl), 4-lower alkylpiperazino, typically 4-methylpiperazino, imidazolino (1-imidazolyl), morpholino (4-morpholinyl), or also thiomorpholino, S-oxo-thiomorpholino, or S,S-dioxothiomorpholino.

[0065] An acyl derived from an organic sulfonic acid, which is designated Ac^2 , is especially one with the subformula $\text{R}^\circ\text{-SO}_2\text{-}$, wherein R° is a hydrocarbyl as defined above in the general and specific meanings, the latter also being generally preferred here. Especially preferred is lower alkylphenylsulfonyl, especially 4-toluenesulfonyl.

[0066] An acyl derived from a phosphoric acid, esterified if necessary, which is designated Ac^3 , is especially one with the subformula $\text{R}^\circ\text{O}(\text{R}^\circ\text{O})\text{P}(=\text{O})\text{-}$, wherein the radicals R° are, independently of one another, as defined in the general and specific meanings indicated above.

[0067] Reduced data on substituents given hereinbefore and hereinafter are considered to be preferences.

[0068] Preferred compounds according to the invention are, for example, those wherein R^0 has the following preferred meanings: lower alkyl, especially methyl or ethyl, amino-lower alkyl, wherein the amino group is unprotected or is protected by a conventional amino protecting group – especially by lower alkoxycarbonyl, typically tert-lower alkoxycarbonyl, for example tert-butoxycarbonyl – e.g. aminomethyl, R,S-, R- or preferably S-1-aminoethyl, tert-butoxycarbonylaminoethyl or R,S-, R-, or preferably S-1-(tert-butoxycarbonylamino)ethyl, carboxy-lower alkyl, typically 2-carboxyethyl, lower alkoxycarbonyl-lower alkyl, typically 2-(tert-butoxycarbonyl)ethyl, cyano-lower alkyl, typically 2-cyanoethyl, tetrahydropyranyloxy-lower alkyl, typically 4-(tetrahydropyranyl)-oxymethyl, morpholino-lower alkyl, typically 2-(morpholino)ethyl, phenyl, lower alkylphenyl, typically 4-methylphenyl, lower alkoxyphenyl, typically 4-methoxyphenyl, imidazolyl-lower alkoxyphenyl, typically 4-[2-(imidazol-1-yl)ethyl]oxyphenyl, carboxyphenyl, typically 4-carboxyphenyl, lower alkoxycarbonylphenyl, typically 4-ethoxycarbonylphenyl or 4-methoxyphenyl, halogen-lower alkylphenyl, typically 4-chloromethylphenyl, pyrrolidinophenyl, typically 4-pyrrolidinophenyl, imidazol-1-ylphenyl, typically 4-(imidazolyl-1-yl)phenyl, piperazinophenyl, typically 4-piperazinophenyl, (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl, morpholinophenyl, typically 4-morpholinophenyl, pyrrolidino-lower alkylphenyl, typically 4-pyrrolidinomethylphenyl,

- 15 -

imidazol-1-yl-lower alkylphenyl, typically 4-(imidazolyl-1-ylmethyl)phenyl, piperazino-lower alkylphenyl, typically 4-piperazinomethylphenyl, (4-lower alkylpiperazinomethyl)-phenyl, typically 4-(4-methylpiperazinomethyl)phenyl, morpholino-lower alkylphenyl, typically 4-morpholinomethylphenyl, piperazinocarbonylphenyl, typically 4-piperazinocarbonylphenyl, or (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl.

[0069] Preferred acyl radicals Ac^1 are acyl radicals of a carboxylic acid which are characterised by the subformula $R^\circ-CO-$, wherein R° has one of the above general and preferred meanings of the hydrocarbyl radical R° . Especially preferred radicals R° here are lower alkyl, especially methyl or ethyl, amino-lower alkyl, wherein the amino group is unprotected or protected by a conventional amino protecting group, especially by lower alkoxy-carbonyl, typically tert-lower alkoxy-carbonyl, for example tert-butoxy-carbonyl, e.g. aminomethyl, R,S-, R-, or preferably S-1-aminoethyl, tert-butoxy-carbonylamino-methyl or R,S-, R-, or preferably S-1-(tert-butoxy-carbonylamino)ethyl, carboxy-lower alkyl, typically 2-carboxyethyl, lower alkoxy-carbonyl-lower alkyl, typically 2-(tert-butoxy-carbonyl)ethyl, tetrahydropyranyloxy-lower alkyl, typically 4-(tetrahydropyranyl)oxymethyl, phenyl, imidazolyl-lower alkoxyphenyl, typically 4-[2-(imidazol-1-yl)ethyl]oxyphenyl, carboxyphenyl, typically 4-carboxyphenyl, lower alkoxy-carbonylphenyl, typically 4-ethoxy-carbonylphenyl, halogen-lower alkylphenyl, typically 4-chloromethylphenyl, imidazol-1-ylphenyl, typically 4-(imidazolyl-1-yl)phenyl, pyrrolidino-lower alkylphenyl, typically 4-pyrrolidinomethylphenyl, piperazino-lower alkylphenyl, typically 4-piperazinomethylphenyl, (4-lower alkylpiperazinomethyl)phenyl, typically 4-(4-methylpiperazinomethyl)phenyl, morpholino-lower alkylphenyl, typically 4-morpholinomethylphenyl, piperazinocarbonylphenyl, typically 4-piperazinocarbonylphenyl, or (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl.

[0070] A further preferred Acyl Ac^1 is derived from monoesters of carbonic acid and is characterised by the subformula $R^\circ-O-CO-$. The lower alkyl radicals, especially tert-butyl, are especially preferred hydrocarbyl radicals R° in these derivatives.

[0071] Another preferred Acyl Ac^1 is derived from amides of carbonic acid (or also thiocarbonic acid) and is characterised by the formula $R^\circ HN-C(=W)-$ or $R^\circ R^\circ N-C(=W)-$, wherein the radicals R° are, independently of one another, as defined above and W is sulfur and especially oxygen. In particular, compounds are preferred wherein Ac^1 is a radical of formula $R^\circ HN-C(=W)-$, wherein W is oxygen and R° has one of the following preferred meanings: morpholino-lower alkyl, typically 2-morpholinoethyl, phenyl, lower alkoxyphenyl,

- 16 -

typically 4-methoxyphenyl or 4-ethoxyphenyl, carboxyphenyl, typically 4-carboxyphenyl, or lower alkoxy-carbonylphenyl, typically 4-ethoxy-carbonylphenyl.

[0072] A preferred acyl Ac^2 of subformula $\text{R}^\circ\text{-SO}_2\text{-}$, wherein R° is a hydrocarbonyl as defined in the above general and specific meanings, is lower alkylphenylsulfonyl, typically 4-toluenesulfonyl.

[0073] If p is 0, the nitrogen atom bonding R_3 is uncharged. If p is 1, then R_4 must also be present, and the nitrogen atom bonding R_3 and R_4 (quaternary nitrogen) is then positively charged.

[0074] The definitions for an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms each, or for a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms each and up to 9 heteroatoms each, or acyl with up to 30 carbon atoms each, preferably match the definitions given for the corresponding radicals R_3 and R_4 . Especially preferred is R_5 lower alkyl, especially methyl, or most especially hydrogen.

[0075] Z is especially lower alkyl, most especially methyl or hydrogen.

[0076] If the two bonds indicated by wavy lines are missing in ring A, then no double bonds (tetra-hydrogenated derivatives) are present between the carbon atoms characterised in formula I by the numbers 1, 2, 3, and 4, but only single bonds, whereas ring B is aromatic (double bonds between the carbon atoms characterised in formula I by 8 and 9 and those characterised by 10 and 11). If the two bonds indicated by wavy lines are missing in ring B, then no double bonds (tetra-hydrogenated derivatives) are present between the carbon atoms characterised in formula I by the numbers 8, 9, 10, and 11, but only single bonds, whereas ring A is aromatic (double bonds between the carbon atoms characterised in formula I by 1 and 2 and those characterised by 3 and 4). If the total of four bonds indicated by wavy lines are missing in rings A and B, and are replaced by a total of 8 hydrogen atoms, then no double bonds (octa-hydrogenated derivatives) are present between the carbon atoms numbered 1, 2, 3, 4, 8, 9, 10, and 11 in formula I, but only single bonds.

[0077] By their nature, the compounds of the invention may also be present in the form of pharmaceutically, i.e. physiologically, acceptable salts, provided they contain salt-forming groups. For isolation and purification, pharmaceutically unacceptable salts may also be used. For therapeutic use, only pharmaceutically acceptable salts are used, and these salts are preferred.

- 17 -

[0078] Thus, compounds of formula I having free acid groups, for example a free sulfo, phosphoryl or carboxyl group, may exist as a salt, preferably as a physiologically acceptable salt with a salt-forming basic component. These may be primarily metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, especially tertiary monoamines and heterocyclic bases, for example triethylamine, tri-(2-hydroxyethyl)-amine, N-ethylpiperidine or N,N'-dimethylpiperazine.

[0079] Compounds of the invention having a basic character may also exist as addition salts, especially as acid addition salts with inorganic and organic acids, but also as quaternary salts. Thus, for example, compounds which have a basic group, such as an amino group, as a substituent may form acid addition salts with common acids. Suitable acids are, for example, hydrohalic acids, e.g. hydrochloric and hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid or perchloric acid, or aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic, acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, fumaric, maleic, hydroxymaleic, oxalic, pyruvic, phenylacetic, benzoic, p-aminobenzoic, anthranilic, p-hydroxybenzoic, salicylic, p-aminosalicylic acid, pamoic acid, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylenedisulfonic, halobenzenesulfonic, toluenesulfonic, naphthalenesulfonic acids or sulfanilic acid, and also methionine, tryptophan, lysine or arginine, as well as ascorbic acid.

[0080] In view of the close relationship between the compounds (especially of formula I) in free form and in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the novel compounds, and of their solvates, any reference hereinbefore and hereinafter to the free compounds is to be understood as referring also to the corresponding salts, and the solvates thereof, for example hydrates, as appropriate and expedient.

[0081] The compounds of formula A, B, C, D, I, II, III, IV, V or VI especially those wherein R₅ is hydrogen, possess valuable pharmacological properties.

[0082] In the case of the groups of radicals or compounds mentioned hereinbefore and hereinafter, general definitions may, insofar as appropriate and expedient, be replaced by the more specific definitions stated hereinbefore and hereinafter.

[0083] Preference is given to a compounds of formula I, II, III, IV, V, VI wherein

- 18 -

[0084] R_1 and R_2 independently of each other are lower alkyl, lower alkyl substituted by halogen, C_6 - C_{14} aryl, hydroxy, lower alkoxy, phenyl-lower alkoxy, phenyloxy, lower alkanoyloxy, benzoyloxy, amino, lower alkylamino, lower alkanoylamino, phenyl-lower alkylamino, N,N-di-lower alkylamino, N,N-di-(phenyl-lower alkyl)amino, cyano, mercapto, lower alkylthio, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl, sulfo, lower alkanesulfonyl, lower alkoxysulfonyl, aminosulfonyl, N-lower alkylaminosulfonyl or N,N-di-lower alkylaminosulfonyl; halogen; lower alkoxy; C_6 - C_{14} aryloxy; C_6 - C_{14} aryl-lower alkoxy; lower alkanoyloxy; C_6 - C_{14} arylcarbonyloxy; amino monosubstituted or disubstituted by lower alkyl, C_6 - C_{14} aryl, C_6 - C_{14} aryl-lower alkyl, lower alkanoyl or C_6 - C_{12} arylcarbonyl; cyano; nitro; mercapto; lower alkylthio; C_6 - C_{14} arylthio; C_6 - C_{14} aryl-lower alkylthio; lower alkanoylthio; C_6 - C_{14} aryl-lower alkanoylthio; carboxy; lower alkoxycarbonyl, C_6 - C_{14} aryl-lower alkoxycarbonyl; C_6 - C_{14} aryloxycarbonyl; carbamoyl; carbamoyl N-mono- or N,N-disubstituted by lower alkyl, C_6 - C_{14} aryl or C_6 - C_{14} aryl-lower alkyl; sulfo; C_6 - C_{14} arylsulfonyl; C_6 - C_{14} aryl-lower alkanesulfonyl; lower alkanesulfonyl; or aminosulfonyl N-mono- or N,N-disubstituted by lower alkyl, C_6 - C_{14} aryl or C_6 - C_{14} aryl-lower alkyl, wherein C_6 - C_{14} aryl is an aryl radical with 6 to 12 carbon atoms in the ring system, which may be unsubstituted or substituted by halogen, phenyl or naphthyl, hydroxy, lower alkoxy, phenyl-lower alkoxy, phenyloxy, lower alkanoyloxy, benzoyloxy, amino, lower alkylamino, lower alkanoylamino, phenyl-lower alkylamino, N,N-di-lower alkylamino, N,N-di-(phenyl-lower alkyl)amino, cyano, mercapto, lower alkylthio, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl, sulfo, lower alkanesulfonyl, lower alkoxysulfonyl, aminosulfonyl, N-lower alkylaminosulfonyl or N,N-di-lower alkylaminosulfonyl;

[0085] n and m are independently of each other 0 or 1 or 2, preferably 0;

[0086] R_3 , R_4 , R_8 , R_{10} are independently of each other hydrogen, lower alkyl, lower alkenyl or lower alkadienyl, which are each unsubstituted or monosubstituted or polysubstituted, preferably monosubstituted or disubstituted by a substituent independently selected from lower alkyl; hydroxy; lower alkoxy, which may be unsubstituted or mono-, di-, or trisubstituted by (i) heterocyclyl with 4 to 12 ring atoms, which may be unsaturated, wholly saturated, or partly saturated, is monocyclic or bicyclic and may contain up to three heteroatoms selected from nitrogen, oxygen and sulfur, and is most especially pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3- or 4-pyridyl, or in a broader sense also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl,

benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, benzothienyl, typically 2- or 3-benzothienyl; imidazolyl, typically 1- or 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, thiazolyl, typically 2-thiazolyl, benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, quinazolyl, typically 2-quinazolinyl, 2-tetrahydrofuryl, 4-tetrahydrofuryl, 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidyl, 1-, 2-, 3-, or 4-piperidyl, 1-, 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl or N,N'-bis-lower alkyl-2-piperazinyl, (ii) by halogen, (iii) by hydroxy or (iv) by lower alkoxy; phenoxy; phenyl-lower alkoxy; heterocycloxy, wherein heterocyclyl is pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3- or 4-pyridyl, or in a broader sense also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, benzothienyl, typically 2- or 3-benzothienyl; imidazolyl, typically 1- or 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, thiazolyl, typically 2-thiazolyl, benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, quinazolyl, typically 2-quinazolinyl, 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidyl, 1-, 2-, 3-, or 4-piperidyl, 1-, 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl or N,N'-bis-lower alkyl-2-piperazinyl, such as especially 2- or 4-tetrahydropyranyloxy; lower alkanoyloxy; carboxy; lower alkoxy-carbonyl; phenyl-lower alkoxy-carbonyl; mercapto; lower alkylthio; phenylthio; halogen; halogen-lower alkyl; oxo (except in the 1-position, because otherwise acyl); azido; nitro; cyano; amino; mono-lower alkylamino; di-lower alkylamino; pyrrolidino; imidazol-1-yl; piperidino; piperazino; 4-lower alkylpiperazino; morpholino; thiomorpholino; diphenylamino or dibenzylamino unsubstituted or substituted in the phenyl part by lower alkyl, lower alkoxy, halogen and/or nitro; lower alkoxy-carbonylamino; phenyl-lower alkoxy-carbonylamino unsubstituted or substituted in the phenyl part by lower alkyl or lower alkoxy; fluorenylmethoxycarbonylamino; amino-lower alkyl; monosubstituted or disubstituted amino-lower alkyl, wherein the amino substituent is selected from lower alkyl, hydroxy-lower alkyl, C₃-C₈cycloalkyl, amino-lower alkyl, N-mono- or N,N-di(-lower alkyl)amino-lower alkyl, amino, N-mono- or N,N-di-lower alkylamino and N-mono- or N,N-di-(hydroxy-lower alkyl)amino; pyrrolidino-lower alkyl; piperidino-lower alkyl; piperazino-lower alkyl; 4-lower alkylpiperazino-lower alkyl; imidazol-1-yl-lower alkyl; morpholino-lower alkyl; thiomorpholino-lower alkyl; S-oxo-thiomorpholino-lower alkyl; S,S-dioxothiomorpholino-lower alkyl; lower alkylendioxy; sulfamoyl; sulfo; carbamoyl; ureido; guanidino; cyano; aminocarbonyl (carbamoyl) and

- 20 -

aminocarbonyloxy, which are substituted by one or two radicals on the nitrogen, wherein the amino substituents are selected independently of one another from the group comprising lower alkyl, hydroxy-lower alkyl, C₃-C₈cycloalkyl, amino-lower alkyl, N-mono- or N,N-di(-lower alkyl)amino-lower alkyl, amino, N-mono- or N,N-di-lower alkylamino and N-mono- or N,N-di-(hydroxy-lower alkyl)amino; pyrrolidinocarbonyl; piperidinocarbonyl; piperazinocarbonyl; 4-lower alkylpiperazinocarbonyl; imidazolinocarbonyl; morpholinocarbonyl; thio-morpholinocarbonyl; S-oxo-thiomorpholinocarbonyl; and S,S-dioxothiomorpholino; phenyl, naphthyl, phenyl-lower alkyl or phenyl-lower alkenyl with a terminal phenyl radical, which is unsubstituted or monosubstituted or disubstituted by the radicals named above as substituents of lower alkyl, lower alkenyl or lower alkadienyl; or heterocyclyl-lower alkyl, wherein heterocyclyl is pyrrolyl, for example 2-pyrrolyl or 3-pyrrolyl, pyridyl, for example 2-, 3- or 4-pyridyl, or in a broader sense also thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl, indolyl, typically 2- or 3-indolyl, quinolyl, typically 2- or 4-quinolyl, isoquinolyl, typically 3- or 5-isoquinolyl, benzofuranyl, typically 2-benzofuranyl, chromenyl, typically 3-chromenyl, benzothienyl, typically 2- or 3-benzothienyl; imidazolyl, typically 1- or 2-imidazolyl, pyrimidinyl, typically 2- or 4-pyrimidinyl, oxazolyl, typically 2-oxazolyl, isoxazolyl, typically 3-isoxazolyl, thiazolyl, typically 2-thiazolyl, benzimidazolyl, typically 2-benzimidazolyl, benzoxazolyl, typically 2-benzoxazolyl, quinazolyl, typically 2-quinazolyl, 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidyl, 1-, 2-, 3-, or 4-piperidyl, 1-, 2- or 3-morpholyl, 2- or 3-thiomorpholyl, 2-piperazyl or N,N'-bis-lower alkyl-2-piperazyl, which in each case are unsubstituted or monosubstituted or disubstituted by the radicals named above as substituents of lower alkyl, lower alkenyl, or lower alkadienyl;

[0087] or acyl of the subformula Y-C(=W)-, wherein W is oxygen and Y is hydrogen, R^o, R^o-O-, R^oHN-, or R^oR^oN- (wherein the radicals R^o may be the same or different),

[0088] or

[0089] acyl of the subformula R^o-SO₂-,

[0090] whereby R₄ may also be absent for the compound of formula II;

[0091] or

[0092] R₄ is absent for compounds of formula II, hydrogen or CH₃ for compounds of formula I, and

[0093] R₃ is acyl of the subformula Y-C(=W)-, wherein W is oxygen and Y is hydrogen, R^o, R^o-O-, R^oHN-, or R^oR^oN- (wherein the radicals R^o may be the same or different),

- 21 -

[0094] or

[0095] is acyl of the subformula $R^0\text{-SO}_2\text{-}$,

[0096] wherein R^0 in the said radicals has the following meanings: substituted or unsubstituted lower alkyl, especially methyl or ethyl, amino-lower alkyl hydroxy-lower alkyl, wherein the amino group is unprotected or is protected by a conventional amino protecting group – especially by lower alkoxycarbonyl, typically tert-lower alkoxycarbonyl, for example tert-butoxycarbonyl – e.g. aminomethyl, R,S-, R- or preferably S-1-aminoethyl, tert-butoxycarbonylaminomethyl or R,S-, R-, or preferably S-1-(tert-butoxycarbonylamino)ethyl, carboxy-lower alkyl, typically 2-carboxyethyl, lower alkoxycarbonyl-lower alkyl, typically 2-(tert-butoxycarbonyl)ethyl, cyano-lower alkyl, typically 2-cyanoethyl, tetrahydropyranyloxy-lower alkyl, typically 4-(tetrahydropyranyl)oxymethyl, morpholino-lower alkyl, typically 2-(morpholino)ethyl, phenyl, lower alkylphenyl, typically 4-methylphenyl, lower alkoxyphenyl, typically 4-methoxyphenyl, imidazolyl-lower alkoxyphenyl, typically 4-[2-(imidazol-1-yl)ethyl]oxyphenyl, carboxyphenyl, typically 4-carboxyphenyl, lower alkoxycarbonylphenyl, typically 4-ethoxycarbonylphenyl or 4-methoxyphenyl, halogen-lower alkylphenyl, typically 4-chloromethylphenyl, pyrrolidinophenyl, typically 4-pyrrolidinophenyl, imidazol-1-ylphenyl, typically 4-(imidazol-1-yl)phenyl, piperazinophenyl, typically 4-piperazinophenyl, (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl, morpholinophenyl, typically 4-morpholinophenyl, pyrrolidino-lower alkylphenyl, typically 4-pyrrolidinomethylphenyl, imidazol-1-yl-lower alkylphenyl, typically 4-(imidazol-1-ylmethyl)phenyl, piperazino-lower alkylphenyl, typically 4-piperazinomethylphenyl, (4-lower alkylpiperazinomethyl)-phenyl, typically 4-(4-methylpiperazinomethyl)phenyl, morpholino-lower alkylphenyl, typically 4-morpholinomethylphenyl, piperazinocarbonylphenyl, typically 4-piperazinocarbonylphenyl, or (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl.

[0097] p is 0 if R_4 is absent, or is 1 if R_3 and R_4 are both present and in each case are one of the aforementioned radicals (for compounds of formula II);

[0098] R_5 is hydrogen or lower alkyl, especially hydrogen,

[0099] X stands for 2 hydrogen atoms, for O, or for 1 hydrogen atom and hydroxy; or for 1 hydrogen atom and lower alkoxy;

[00100] Z is hydrogen or especially lower alkyl, most especially methyl;

- 22 -

[00101] and for compounds for formula II, either the two bonds characterised by wavy lines are preferably absent in ring A and replaced by 4 hydrogen atoms, and the two wavy lines in ring B each, together with the respective parallel bond, signify a double bond;

[00102] or also the two bonds characterised by wavy lines are absent in ring B and replaced by a total of 4 hydrogen atoms, and the two wavy lines in ring A each, together with the respective parallel bond, signify a double bond;

[00103] or both in ring A and in ring B all of the 4 wavy bonds are absent and are replaced by a total of 8 hydrogen atoms;

[00104] or a salt thereof, if at least one salt-forming group is present.

[00105] Particular preference is given to a compound of formula I wherein;

[00106] m and n are each 0;

[00107] R₃ and R₄ are independently of each other

hydrogen, lower alkyl unsubstituted or mono- or disubstituted, especially monosubstituted, by radicals selected independently of one another from carboxy; lower alkoxy carbonyl; and cyano;

[00108] or

[00109] R₄ is hydrogen or -CH₃, and

[00110] R₃ is as defined above or preferably R₃ is, acyl of the subformula R°-CO, wherein R° is lower alkyl; amino-lower alkyl, wherein the amino group is present in unprotected form or is protected by lower alkoxy carbonyl; tetrahydropyranyloxy-lower alkyl; phenyl; imidazolyl-lower alkoxyphenyl; carboxyphenyl; lower alkoxy carbonylphenyl; halogen-lower alkylphenyl; imidazol-1-ylphenyl; pyrrolidino-lower alkylphenyl; piperazino-lower alkylphenyl; (4-lower alkylpiperazinomethyl)phenyl; morpholino-lower alkylphenyl; piperazinocarbonylphenyl; or (4-lower alkylpiperazino)phenyl;

[00111] or is acyl of the subformula R°-O-CO-, wherein R° is lower alkyl;

[00112] or is acyl of the subformula R°HN-C(=W)-, wherein W is oxygen and R° has the following meanings: morpholino-lower alkyl, phenyl, lower alkoxyphenyl, carboxyphenyl, or lower alkoxy carbonylphenyl;

- 23 -

[00113] or R_3 is lower alkylphenylsulfonyl, typically 4-toluenesulfonyl, wherein further specific examples of preferred R_3 groups are described below for the preferred compounds of formula II,

[00114] R_5 is hydrogen or lower alkyl, especially hydrogen,

[00115] X stands for 2 hydrogen atoms or for O;

[00116] Z is methyl or hydrogen;

[00117] or a salt thereof, if at least one salt-forming group is present.

[00118] Particular preference is given to a compound of formula II wherein

[00119] m and n are each 0;

[00120] R_3 and R_4 are independently of each other: hydrogen, lower alkyl unsubstituted or mono- or disubstituted, especially monosubstituted, by radicals selected independently of one another from carboxy; lower alkoxycarbonyl; and cyano; whereby R_4 may also be absent;

[00121] or

[00122] R_4 is absent, and

[00123] R_3 is acyl from the subformula R^o -CO, wherein R^o is lower alkyl, especially methyl or ethyl; amino-lower alkyl, wherein the amino group is unprotected or protected by lower alkoxycarbonyl, typically tert-lower alkoxycarbonyl, for example tert-butoxycarbonyl, e.g. aminomethyl, R,S-, R-, or preferably S-1-aminoethyl, tert-butoxycarbonylaminoethyl or R,S-, R-, or preferably S-1-(tert-butoxycarbonylamino)ethyl; tetrahydropyranyloxy-lower alkyl, typically 4-(tetrahydropyranyl)oxymethyl; phenyl; imidazolyl-lower alkoxyphenyl, typically 4-[2-(imidazol-1-yl)ethyl]oxyphenyl; carboxyphenyl, typically 4-carboxyphenyl; lower alkoxycarbonylphenyl, typically 4-methoxy- or 4-ethoxycarbonylphenyl; halogen-lower alkylphenyl, typically 4-chloromethylphenyl; imidazol-1-ylphenyl, typically 4-(imidazol-1-yl)-phenyl; pyrrolidino-lower alkylphenyl, typically 4-pyrrolidinomethylphenyl; piperazino-lower alkylphenyl, typically 4-piperazinomethylphenyl; (4-lower alkylpiperazinomethyl)phenyl, typically 4-(4-methylpiperazinomethyl)phenyl; morpholino-lower alkylphenyl, typically 4-morpholinomethylphenyl; piperazinocarbonylphenyl, typically 4-piperazinocarbonylphenyl; or (4-lower alkylpiperazino)phenyl, typically 4-(4-methylpiperazino)phenyl;

[00124] or is acyl of the subformula R^o -O-CO-, wherein R^o is lower alkyl;

- 24 -

[00125] or is acyl of the subformula $R^{\circ}HN-C(=W)-$, wherein W is oxygen and R° has the following preferred meanings: morpholino-lower alkyl, typically 2-morpholinoethyl, phenyl, lower alkoxyphenyl, typically 4-methoxyphenyl or 4-ethoxyphenyl, carboxyphenyl, typically 4-carboxyphenyl, or lower alkoxycarbonylphenyl, typically 4-ethoxycarbonylphenyl;

[00126] or is lower alkylphenylsulfonyl, typically 4-toluenesulfonyl;

[00127] p is 0 if R_4 is absent, or is 1 if R_3 and R_4 are both present and in each case are one of the aforementioned radicals;

[00128] R_5 is hydrogen or lower alkyl, especially hydrogen,

[00129] X stands for 2 hydrogen atoms or for O;

[00130] Z is methyl or hydrogen;

[00131] and either the two bonds characterised by wavy lines are preferably absent in ring A and replaced by 4 hydrogen atoms, and the two wavy lines in ring B each, together with the respective parallel bond, signify a double bond;

[00132] or also the two bonds characterised by wavy lines are absent in ring B and replaced by a total of 4 hydrogen atoms, and the two wavy lines in ring A each, together with the respective parallel bond, signify a double bond;

[00133] or both in ring A and in ring B all of the 4 wavy bonds are absent and are replaced by a total of 8 hydrogen atoms;

[00134] or a salt thereof, if at least one salt-forming group is present.

[00135] Most especially preferred compounds of formula II are selected from;

8,9,10,11-Tetrahydrostaurosporine;

N-[4-(4-methylpiperazin-1-ylmethyl)benzoyl]-1,2,3,4-tetrahydrostaurosporine;

N-(4-chloromethylbenzoyl)-1,2,3,4-tetrahydrostaurosporine;

N-(4-(pyrrolidin-1-ylmethyl)benzoyl)-1,2,3,4-tetrahydrostaurosporine;

N-(4-(morpholin-4-ylmethyl)benzoyl)-1,2,3,4-tetrahydrostaurosporine;

N-(4-(piperazin-1-ylmethyl)benzoyl)-1,2,3,4-tetrahydrostaurosporine;

- 25 -

N-ethyl-1,2,3,4-tetrahydrostaurosporine;

N-tosyl-1,2,3,4-tetrahydrostaurosporine;

N-trifluoroacetyl-1,2,3,4-tetrahydrostaurosporine;

N-[4-(2-imidazol-1-yl-ethoxy)benzoyl]-1,2,3,4-tetrahydrostaurosporine;

N-methoxycarbonylmethyl-1,2,3,4-tetrahydrostaurosporine;

N-carboxymethyl-1,2,3,4-tetrahydrostaurosporine;

N-terephthaloylmethyl ester-1,2,3,4-tetrahydrostaurosporine;

N-terephthaloyl-1,2,3,4-tetrahydrostaurosporine;

N-(4-ethylpiperazinylcarbonylbenzoyl)-1,2,3,4-tetrahydrostaurosporine;

N-(2-cyanoethyl)-1,2,3,4-tetrahydrostaurosporine;

N-benzoyl-1,2,3,4-tetrahydrostaurosporine;

N,N-dimethyl -1,2,3,4-tetrahydrostaurosporinium iodide;

N-BOC-glycyl-1,2,3,4-tetrahydrostaurosporine;

N-glycyl-1,2,3,4-tetrahydrostaurosporine;

N-(3-(tert-butoxycarbonyl)propyl)-1,2,3,4-tetrahydrostaurosporine;

N-(3-carboxypropyl)-1,2,3,4-tetrahydrostaurosporine;

N-(4-imidazol-1-yl)benzoyl]-1,2,3,4-tetrahydrostaurosporine;

N-[(tetrahydro-2h-pyran-4-yloxy)acetyl]-1,2,3,4-tetrahydrostaurosporine;

N-BOC-L-alanyl-1,2,3,4-tetrahydrostaurosporine;

N-L-alanyl-1,2,3,4-tetrahydrostaurosporine hydrochloride;

- 26 -

N-methyl-1,2,3,4-tetrahydro-6-methylstaurosporine;

N-(4-carboxyphenylaminocarbonyl)-1,2,3,4-tetrahydrostaurosporine;

N-(4-ethylphenylaminocarbonyl)-1,2,3,4-tetrahydrostaurosporine;

N-(N-phenylaminocarbonyl)-1,2,3,4-tetrahydrostaurosporine;

N-(N-[2-(1-morpholino)ethyl]aminocarbonyl)-1,2,3,4-tetrahydrostaurosporine;

N-(N-[4-methoxyphenyl]aminocarbonyl)-1,2,3,4-tetrahydrostaurosporine;

1,2,3,4-tetrahydro-6-methylstaurosporine;

N-BOC-1,2,3,4-tetrahydrostaurosporine;

N-BOC-1,2,3,4-tetrahydro-6-methylstaurosporine;

N-BOC-1,2,3,4-tetrahydro-6-methyl-7-oxo-staurosporine;

1,2,3,4,8,9,10,11-octahydrostaurosporine;

or a pharmaceutically acceptable salt thereof, if at least one salt-forming group is present.


[00136] Most especially preferred is the compound of formula I designated 1,2,3,4-tetrahydrostaurosporine, or a (particularly pharmaceutically acceptable) salt thereof (here, m and n in formula I are 0, R₃ is hydrogen, R₄ is absent, provided no salt is present (p = 0), or is hydrogen if a salt is present (p = 1), R₅ is hydrogen, the two bonds represented by wavy lines are absent in Ring A and are replaced by a total of 4 hydrogen atoms and the two bonds represented by wavy lines in Ring B are in each case a double bond together with the parallel bonds, X stands for 2 hydrogen atoms, and Z is methyl).

[00137] Most especially preferred are the compounds of formula A wherein;

A) X= O; R₁, R₂, R₅ = H; Q= -(CH₂)₂-O-CH(CH₂)OH-(CH₂)₂-

B) X= O; R₁, R₂, R₅ = H; Q= -(CH₂)₂-O-CH(CH₂N(CH₃)₂)-(CH₂)₂-


- 27 -



C) X= 2 hydrogen atoms; R₁, R₂, R₅ = H; Q=

[00138] Most especially preferred are the compounds of formula I wherein;

- A) X= 2 hydrogen atoms; R₁, R₂, R₃, R₅ = H; R₄= CH₃; Z=CH₃ (staurosporine)
 B) X= 1 hydrogen and 1 hydroxy atoms in (R) or (S) isomeric form; R₁, R₂, R₃, R₅ = H; R₄= CH₃; Z=CH₃ (UCN-01 and UCN-02)
 C) X= 2 hydrogen atoms; R₁, R₂, R₅ = H; R₄= CH₃; R₃= benzoyl; Z=CH₃ (CGP41251 or PKC412 or MIDOSTAURIN)
 D) X= O; R₁, R₂, R₅ = H; R₃= CH₃; R₄= ethyloxycarbonyl; Z=CH₃ (NA 382 ; CAS=143086-33-3)
 E) X= 1 hydrogen and 1 hydroxy atom; R₁, R₂, R₅ = H; R₃= CH₃; Z=CH₃; and R₄ is selected from -(CH₂)₂OH; -CH₂CH(OH)CH₂OH; -CO(CH₂)₂CO₂Na; -(CH₂)₃CO₂H; -COCH₂N(CH₃)₂;



- F) X= 2 hydrogen atoms; R₁, R₂, R₅ = H; R₃= CH₃; Z=CH₃; and R₄ is selected from N-[0-(tetrahydropyran-4-yl)-D-lactoyl]; N-[2-methyl-2-(tetrahydropyran-4-yloxy)-propionyl]; N-[0-(tetrahydropyran-4-yl)-L-lactoyl]; N-[0-(tetrahydropyran-4-yl)-D-lactoyl]; N-[2-(tetrahydro-pyran-4-yloxy)-acetyl]
 G) X=O; R₁, R₂, R₅ = H; R₃= CH₃; Z=CH₃; and R₄ is selected from N-[0-(tetrahydropyran-4-yl)-D-lactoyl]; N-[2-(tetrahydro-pyran-4-yloxy)-acetyl]
 H) X=1 hydrogen and 1 hydroxy atom ; R₁, R₂, R₅ = H; R₃= CH₃; Z=CH₃; and R₄ is selected from N-[0-(tetrahydropyran-4-yl)-D-lactoyl]; N-[2-(tetrahydro-pyran-4-yloxy)-acetyl]

[00139] The abbreviation "CAS" means the CHEMICAL ABSTRACTS registry number.

[00140] The most preferred compounds of formula I e.g. MIDOSTAURIN [International Nonproprietary Name] are covered and have been specifically described by the European patent No. 0 296 110 published on December 21, 1988, as well as in US patent No. 5,093,330 published on March 3, 1992, and Japanese Patent No. 2 708 047. Other preferred compounds are covered and described by the patent applications WO 95/32974 and WO

- 28 -

95/32976 both published on December 7, 1995. All the compounds described in these documents are incorporated into the present application by reference.

[00141] Most especially preferred are the compounds of formula III wherein;

- A) X= 2 hydrogen atoms; R₁, R₂, R₅ = H; R₆= CH₃; R₇= methyloxycarbonyl; Z=H (2-methyl K252a)
- B) X= 2 hydrogen atoms; R₁, R₂, R₅, R₆ = H; R₇= methyloxycarbonyl; Z= H (K-252a)
- C) X= 2 hydrogen atoms; R₁, R₂, R₅, R₆ = H; R₇= methyloxycarbonyl; Z= CH₃ (KT-5720)

[00142] Most especially preferred are the compounds of formula IV wherein;

- A) X= O; R₁, R₂, R₅ = H; R₉= CH₂-NMe₂; R₈= CH₃ ; m'=n'=2
- B) X= O; R₁, R₂, R₅ = H; R₉= CH₂-NH₂; R₈= CH₃ ; m'=2; n'=1 (Ro-31-8425; CAS=151342-35-7)

[00143] Most especially preferred are the compounds of formula V wherein;

- A) X= O; R₁, R₂, R₅ = H; R₈= CH₃; R₁₀= -(CH₂)₃-NH₂; (Ro-31-7549; CAS=138516-31)
- B) X= O; R₁, R₂, R₅ = H; R₈= CH₃; R₁₀= -(CH₂)₃-S-(C=NH)-NH₂; (Ro-31-8220 ; CAS=125314-64-9))
- C) X= O; R₁, R₂, R₅ = H; R₈= CH₃; R₁₀= -CH₃;

[00144] Most especially preferred are the compounds of formula VI wherein;

- A) X= 2 hydrogen atoms; R₁, R₂, R₅ = H; R₄= CH₃; Z=CH₃ ; R₃ selected from methyl or (C₁-C₁₀)alkyl, arylmethyl, C₆H₂CH₂-

[00145] STAUROSPORINE DERIVATIVES and their manufacturing process have been specifically described in many prior documents, well known by the man skilled in the art.

[00146] Compounds of formula A, B, C, D and their manufacturing process have for instance, been described in the European patents No. 0 657 458 published on June 14, 1995, in the European patents No. 0 624 586 published on November 17, 1994, in the European patents No. 0 470 490 published on February 12, 1992, in the European patents No. 0 328 026 published on August 16, 1989, in the European patents No. 0 384 349 published on August 29, 1990, as well as in many publications such as *Barry M. Trost* and Weiping Tang Org. Lett.*, 3(21), 3409-3411.

- 29 -

[00147] Compounds of formula I and their manufacturing processes have specifically been described in the European patents No. 0 296 110 published on December 21, 1988, as well as in US patent No. 5;093,330 published on March 3, 1992, and Japanese Patent No. 2 708 047. Compounds of formula I having a tetrahydropyran-4-yl)-lactoyl substitution on R₄ have been described in the European patent No. 0 624 590 published on November 17, 1994. Other compounds have been described in the European patent No. 0 575 955 published December 29, 1993, European patent No. 0 238 011 published on September 23, 1987 (UCN-O1), International patent application EP98/04141 published as WO99/02532 on July 03, 1998.

[00148] Compounds of formula II and their manufacturing processes have specifically been described in the European patents No. 0 296 110 published on December 21, 1988, as well as in US patent No. 5;093,330 published on March 3, 1992, and Japanese Patent No. 2 708 047.

[00149] Compounds of formula III and their manufacturing processes have specifically been described in the patent applications claiming the priority of the US patent application US 920102 filed on July 24, 1992. (i.e European patents No. 0 768 312 published on April 16, 1997, No. 1 002 534 published May 24, 2000, No. 0 651 754 published on May 10, 1995).

[00150] Compounds of formula IV and their manufacturing processes have specifically been described in the patent applications claiming the priority of the British patent applications GB 9309602 and GB 9403249 respectively filed on May 10, 1993, and on February 21, 1994. (i.e European patents No. 0 624 586 published on November 17, 1994, No. 1 002 534 published May 24, 2000, No. 0 651 754 published on May 10, 1995).

[00151] Compounds of formula V and their manufacturing processes have specifically been described in the patent applications claiming the priority of the British patent applications GB 8803048, GB 8827565, GB 8904161 and GB 8928210 respectively filed on February 10, 1988, November 25, 1988, February 23, 1989 and December 13, 1989. (i.e European patents No. 0 328 026 published on August 16, 1989, and No. 0 384 349 published August 29, 1990).


[00152] Compounds of formula VI and their manufacturing processes have specifically been described in the patent applications claiming the priority of the US patent applications 07/777,395 (Con), filed on October 10, 1991 (i.e International patent application WO 93/07153 published on April 15, 1993).

- 30 -

[00153] In each case where citations of patent applications or scientific publications are given in particular for the STAUROSPORINE DERIVATIVE compounds, the subject-matter of the final products, the pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications.

[00154] The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.

[00155] The preferred STAUROSPORINE DERIVATIVE according to the invention is *N*-[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide of the formula (VII):



(VII)

or a salt thereof, (hereinafter: "Compound of formula VII or MIDOSTAURIN").

[00156] Compound of formula VII is also known as MIDOSTAURIN [International Nonproprietary Name] or PKC412.

[00157] MIDOSTAURIN is a derivative of the naturally occurring alkaloid staurosporine, and has been specifically described in the European patent No. 0 296 110 published on December 21, 1988, as well as in US patent No. 5,093,330 published on March 3, 1992, and Japanese Patent No. 2 708 047.

- 31 -

[00158] Further the invention provides the use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) for the preparation of a medicament for use in the treatment of a proliferative disease.

[00159] In a further aspect the invention provides use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) for the treatment of a proliferative disease, especially a sarcoma, more especially aRMS.

[00160] In yet further aspect the invention provides a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as active ingredient for use in the treatment of a proliferative disease, especially a sarcoma, more especially aRMS.

[00161] In still yet further aspect the invention provides a package comprising a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) together with instructions for the use for the treatment of a proliferative disease, especially a sarcoma, more especially aRMS.

[00162] The term "delay of progression" as used herein means administration of the composition to patients being in an early phase of the proliferative disease to be treated.

[00163] The term "solid tumor disease" as used herein comprises, but is not restricted to glioma, thyroid cancer, breast cancer, ovarian cancer, cancer of the colon and generally the GI tract, cervix cancer, lung cancer, in particular small-cell lung cancer, and non-small-cell lung cancer, head and neck cancer, bladder cancer, cancer of the prostate, or a sarcoma such as Kaposi's sarcoma or Alveolar Rhabdomyosarcoma. In one preferred embodiment of the invention, the tumor disease to be treated is Alveolar Rhabdomyosarcoma, glioma, cancer of the prostate or thyroid cancer. The present composition inhibits the growth of solid tumors, but also liquid tumors. Furthermore, depending on the tumor type and the particular composition used, a decrease of the tumor volume can be obtained. The composition disclosed herein is also suited to prevent the metastatic spread of tumors and the growth or development of micrometastases.

[00164] The nature of proliferative diseases like solid tumor diseases is multifactorial. Under certain circumstances, drugs with different mechanisms of action may be combined. However, just considering any combination of drugs having different mode of action does not necessarily lead to combinations with advantageous effects.

- 32 -

[00165] In one embodiment, the composition of the invention is administered in combination with radiation. Combination refers to administration of an amount of a compound of formula I in combination with administration of an amount of ionizing radiation such that there is a synergistic effect which would not be obtained if a compound of formula I is administered without separate, simultaneous or sequential administration of ionizing radiation. Wherein administration of ionizing radiation can be continuous, sequential or sporadic. Or an effect which would not be obtained if there is administered ionizing radiation without the separate, simultaneous or sequential administration of a compound of formula I, wherein administration can be continuous, sequential or sporadic.

[00166] Preferably combination refers to administration of an amount of a compound of formula I in combination with administration of an amount of ionizing radiation such that there is a synergistic antiproliferative effect and/ or a clonogenic cell killing effect that would not be obtained if

- a. The compound of formula I is administered without prior, simultaneous or subsequent administration of ionizing radiation. Wherein administration can be continuous, sequential or sporadic;
- b. There is administration of ionizing radiation without the prior, simultaneous or subsequent administration of a compound of formula I. Where in administration can be continuous, sequential or sporadic.

[00167] The term "ionising radiation" referred to above and hereinafter means ionising radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionising radiation is provided in, but not limited to, radiation therapy and is known in the art (Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, 248-275 (Devita et al., ed., 4th Ed., V1, 1993).

[00168] In another combination of the invention, compounds of formula I and pharmaceutically acceptable salts and prodrug derivatives are preferably used in the form of pharmaceutical preparations that contain the relevant therapeutically effective amount of active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.

[00169] In a preferred embodiment, each patient receives doses of ionizing radiation during the same period and the compound of formula I.

- 33 -

[00170] In an alternative embodiment, the ionizing radiation is given as a pre-treatment, i.e. before the treatment with the COMPOSITION OF THE INVENTION is started; the ionizing radiation alone is administered to the patient for a defined period of time, e.g. daily administration of the ionizing radiation alone for two or three days or weeks.

[00171] As mentioned above the precise dosage of the FLT-3 inhibitor to be employed for treating the diseases and conditions mentioned hereinbefore depends upon several factors including the host, the nature and the severity of the condition being treated, the mode of administration. However, in general, satisfactory results are achieved when the FLT-3 inhibitor is administered parenterally, e.g., intraperitoneally, intravenously, intramuscularly, subcutaneously, intratumorally, or rectally, or enterally, e.g., orally, preferably intravenously or, preferably orally, intravenously at a daily dosage of 0.1 to 10 mg/kg body weight, preferably 1 to 5 mg/kg body weight. In human trials a total dose of 225 mg/day was most presumably the Maximum Tolerated Dose (MTD). A preferred intravenous daily dosage is 0.1 to 10 mg/kg body weight or, for most larger primates, a daily dosage of 200-300 mg. A typical intravenous dosage is 3 to 5 mg/kg, three to five times a week.

[00172] Most preferably, the FLT-3 inhibitors, especially MIDOSTAURIN, are administered orally, by dosage forms such as microemulsions, soft gels or solid dispersions in dosages up to about 250 mg/day, in particular 225 mg/day, administered once, twice or three times daily.

[00173] Usually, a small dose is administered initially and the dosage is gradually increased until the optimal dosage for the host under treatment is determined. The upper limit of dosage is that imposed by side effects and can be determined by trial for the host being treated.

[00174] The FLT-3 inhibitor may be combined with one or more pharmaceutically acceptable carriers and, optionally, one or more other conventional pharmaceutical adjuvants and administered enterally, e.g. orally, in the form of tablets, capsules, caplets, etc. or parenterally, e.g., intraperitoneally or intravenously, in the form of sterile injectable solutions or suspensions. The enteral and parenteral compositions may be prepared by conventional means.

[00175] The infusion solutions according to the present invention are preferably sterile. This may be readily accomplished, e.g. by filtration through sterile filtration membranes. Aseptic formation of any composition in liquid form, the aseptic filling of vials and/or combining a pharmaceutical composition of the present invention with a suitable diluent under aseptic conditions are well known to the skilled addressee.

- 34 -

[00176] The FLT-3 inhibitor may be formulated into enteral and parenteral pharmaceutical compositions containing an amount of the active substance that is effective for treating the diseases and conditions named hereinbefore, such compositions in unit dosage form and such compositions comprising a pharmaceutically acceptable carrier.

[00177] Examples of useful compositions of FLT-3 inhibitors are described in the European patents No. 0 296 110, No. 0 657 164, No. 0 296 110, No.0 733 372, No.0 711 556, No.0 711 557.

[00178] The preferred compositions of FLT-3 inhibitors are described in the European patent No. 0 657 164 published on June 14, 1995. The described pharmaceutical compositions comprise a solution or dispersion of compounds of formula I such as MIDOSTAURIN in a saturated polyalkylene glycol glyceride, in which the glycol glyceride is a mixture of glyceryl and polyethylene glycol esters of one or more C₈-C₁₈ saturated fatty acids.

[00179] Two manufacture processes of such compositions of FLT-3 inhibitors are described hereafter.

[00180] Composition A:

[00181] Gelucire 44/14 (82 parts) is melted by heating to 60° C. Powdered MIDOSTAURIN (18 parts) is added to the molten material. The resulting mixture is homogenised and the dispersion obtained is introduced into hard gelatin capsules of different size, so that some contain a 25mg dosage and others a 75mg dosage of the MIDOSTAURIN. The resulting capsules are suitable for oral administration.

[00182] Composition B:

[00183] Gelucire 44/14 (86 parts) is melted by heating to 60° C. Powdered MIDOSTAURIN (14 parts) is added to the molten material. The mixture is homogenised and the dispersion obtained is introduced into hard gelatin capsules of different size, so that some contain a 25mg dosage and others a 75mg dosage of the MIDOSTAURIN. The resulting capsules are suitable for oral administration.

[00184] Gelucire 44/14 available commercially from Gattefossé; is a mixture of esters of C₈-C₁₈ saturated fatty acids with glycerol and a polyethylene glycol having a molecular weight of about 1500, the specifications for the composition of the fatty acid component being, by weight, 4-10% caprylic acid, 3-9% capric acid, 40-50% lauric acid, 14-24% myristic acid, 4-14% palmitic acid and 5-15% stearic acid.

- 35 -

[00185] A preferred example of Gelucire formulation consists of:

Gelucire (44/14): 47 g

MIDOSTAURIN: 3.0g filled into a 60 mL Twist off flask

[00186] A preferred example of soft gel will contain the following Microemulsion:

Cornoil glycerides	85.0 mg
Polyethylen glykol 400	128.25 mg
Cremophor RH 40	213.75 mg
MIDOSTAURIN	25.0 mg
DL alpha Tocopherol	0.5 mg
Ethanol absolute	33.9 mg
Total	486.4 mg

[00187] However, it should be clearly understood that it is for purposes of illustration only.

[00188] In particular, a therapeutically effective amount of each combination partner of the COMPOSITION OF THE INVENTION may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination. For example, the method of delay of progression or treatment of a proliferative disease according to the invention may comprise (i) administration of the first combination partner and (ii) administration of the second combination partner, wherein administration of a combination partner may be simultaneous or sequential in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily or weekly dosages corresponding to the amounts described herein. The individual combination partners of the COMPOSITION OF THE INVENTION can be administered separately at different times during the course of therapy or concurrently. Furthermore, the term administering also encompasses the use of a pro-drug of a compound of formula I that converts *in vivo* to the combination partner as such. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

[00189] The dosage of ionizing radiation and a compound of formula I in relation to each other is preferably in a ratio that is synergistic.


- 36 -

[00190] The particular mode of administration and the dosage of a compound of formula I may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, etc.

[00191] The dosage of a compound of formula I may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, effectiveness and duration of action of the ionizing radiation and/or sex, age, weight and individual condition of the subject to be treated.

[00192] The dosage of ionizing radiation may depend on various factors, such as effectiveness and duration of action of the ionizing radiation, mode of administration, location of administration, effectiveness and duration of action of the compound of formula I and/or sex, age, weight and individual condition of the subject to be treated. The dosage of ionizing radiation is generally defined in terms of radiation absorbed dose, time and fraction, and must be carefully defined by the attending physician.

[00193] In one preferred embodiment of the invention the combination comprises *N*-[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide of the formula (VII):



or a salt thereof.

[00194] Moreover, the present invention relates to a method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a

- 37 -

COMPOSITION OF THE INVENTION in a way that is jointly therapeutically effective against a proliferative disease and in which the combination partners can also be present in the form of their pharmaceutically acceptable salts.

[00195] Furthermore, the present invention pertains to the use of a COMPOSITION OF THE INVENTION for the delay of progression or treatment of a proliferative disease and for the preparation of a medicament for the delay of progression or treatment of a proliferative disease.

[00196] In one embodiment of the invention, an antidiarrheal agent is administered together with the COMPOSITION OF THE INVENTION in order to prevent, control or eliminate diarrhoea that is sometimes associated with the administration of a compound of formula I. Thus, the present invention also relates to a method of preventing or controlling diarrhoea associated with administering a compound of formula I, which comprises administering an effective amount of an antidiarrhea agent to the patient receiving treatment with the COMPOSITION OF THE INVENTION. Antidiarrheal agents and protocols for their administration are known to those skilled in the art. Antidiarrheal agents suitable for use in the inventive methods and compositions include, but are not limited to, natural opioids, such as tincture of opium, paregoric, and codeine, synthetic opioids, such as diphenoxylate, difenoxin and loperamide, bismuth subsalicylate, octreotide (e.g. available as SANDO-STATINTM), motilin antagonists and traditional antidiarrheal remedies, such as kaolin, pectin, berberine and muscarinic agents.

[00197] The following example is intended to illustrate the invention and are not to be construed as being limitations thereon.

[00198] Example 1

[00199] Products of chromosomal translocations play a crucial role both in the oncogenic process and as targets for therapeutic intervention. However, unlike BCR/ABL whose kinase activity can be specifically inhibited by a small molecule (Glivec), most chromosomal translocations upregulate native or generate chimeric oncogenic transcription factors which in general are less amendable to small molecule inhibition.

[00200] Recently, we have established a gene signature characteristic for the Pediatric sarcoma alveolar rhabdomyosarcoma (aRMS), which expresses the chimaeric fusion protein PAX3/FKHR due to a chromosomal translocation event t(2;13). Based on this signature, a

- 38 -

number of potential therapeutic target molecules have been selected for further study, such as FGFR2. Here, we now demonstrate that PKC412, a staurosporine derivative originally developed against PKC, can efficiently inhibit cell growth of aRMS cells in vitro and induce apoptosis due to enhanced caspase 3 activity. Furthermore, tumor growth could also be inhibited in vivo using a mouse xenograft tumor model.



[00201] Because specific downregulation of PAX3/FKHR by either siRNA or antisense oligonucleotides can similarly induce apoptosis in aRMS cells, we investigated any potential effects of PKC412 on PAX3/FKHR by analyzing expression of specific target genes such as CB1. Interestingly, CB1 expression was completely abolished upon treatment with PKC412 suggesting that the compound regulates the activity of PAX3/FKHR. Surprisingly, this inhibition was also observed with PAX3/NCOA1, which thus suggests that the PAX3 part of the fusion proteins is the target of the inhibitory function of PKC412. Finally, we identified several phosphorylation sites in the PAX3 region which potentially act as regulators of its activity.

[00202] These experiments suggest that treatment of aRMS with PKC412 leads to induction of apoptotic cell death and tumor growth inhibition in vitro and in vivo, likely mediated via inhibition of the activity of PAX3/FKHR, a chimaeric oncogenic transcription factor.

- 39 -


Claims

1. A method for treating a proliferative disease in a subject in need of such treatment, wherein the method comprises administering a compound selected from the compounds of formula



or

or



or

or

- 40 -

wherein R_1 and R_2 , are, independently of one another, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

n and m are, independently of one another, a number from and including 0 to and including 4;

n' and m' are, independently of one another, a number from and including 1 to and including 4;

R_3 , R_4 , R_8 and R_{10} are, independently of one another, hydrogen, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, an acyl with up to 30 carbon atoms, wherein R_4 may also be absent;

or R_3 is acyl with up to 30 carbon atoms and R_4 not an acyl;

p is 0 if R_4 is absent, or is 1 if R_3 and R_4 are both present and in each case are one of the aforementioned radicals;

R_5 is hydrogen, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms;

R_7 , R_6 and R_9 are acyl or -(lower alkyl) -acyl, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, carbonyl, carbonyldioxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

- 41 -

X stands for 2 hydrogen atoms; for 1 hydrogen atom and hydroxy; for O; or for hydrogen and lower alkoxy;

Z stands for hydrogen or lower alkyl;

and either the two bonds characterised by wavy lines are absent in ring A and replaced by 4 hydrogen atoms, and the two wavy lines in ring B each, together with the respective parallel bond, signify a double bond;


or the two bonds characterised by wavy lines are absent in ring B and replaced by a total of 4 hydrogen atoms, and the two wavy lines in ring A each, together with the respective parallel bond, signify a double bond;

or both in ring A and in ring B all of the 4 wavy bonds are absent and are replaced by a total of 8 hydrogen atoms;

or a salt thereof, if at least one salt-forming group is present;

and the proliferative disease is associated with a PAX/FKHR translocation.

2. A method according to claim 1 which comprises administering a compound of formula I,



wherein

m and n are each 0;

R₃ and R₄ are independently of each other hydrogen,

- 42 -

lower alkyl unsubstituted or mono- or disubstituted, especially monosubstituted, by radicals selected independently of one another from carboxy; lower alkoxycarbonyl; and cyano;
or

R₄ is hydrogen or -CH₃, and

R₃ is acyl of the subformula R^o-CO-, wherein R^o is lower alkyl; amino-lower alkyl, wherein the amino group is present in unprotected form or is protected by lower alkoxycarbonyl; tetrahydropyranyloxy-lower alkyl; phenyl; imidazolyl-lower alkoxyphenyl; carboxyphenyl; lower alkoxycarbonylphenyl; halogen-lower alkylphenyl; imidazol-1-ylphenyl; pyrrolidino-lower alkylphenyl; piperazino-lower alkylphenyl; (4-lower alkylpiperazinomethyl)phenyl; morpholino-lower alkylphenyl; piperazinocarbonylphenyl; or (4-lower alkylpiperazino)phenyl;

or is acyl of the subformula R^o-O-CO-, wherein R^o is lower alkyl;

or is acyl of the subformula R^oHN-C(=W)-, wherein W is oxygen and R^o has the following meanings: morpholino-lower alkyl, phenyl, lower alkoxyphenyl, carboxyphenyl, or lower alkoxycarbonylphenyl;

or R₃ is lower alkylphenylsulfonyl, typically 4-toluenesulfonyl;

R₅ is hydrogen or lower alkyl,

X stands for 2 hydrogen atoms or for O;

Z is methyl or hydrogen;

or a salt thereof, if at least one salt-forming group is present;

and the proliferative disease is associated with a PAX/FKHR translocation.

3. A method according to claim 1 or 2 which comprises administering *N*-[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide.

4. A method according to claims 1, 2 or 3 wherein subject is a warm-blooded animal having a proliferative disease comprising administering to the animal a composition according to any of claims 1, 2 or 3 in a way that is therapeutically effective against a proliferative disease.

- 43 -

5. A method according to any of claims 1 to 4 which comprises administering a quantity that is therapeutically effective against a proliferative disease of a compound of formula I and at least one pharmaceutically acceptable carrier.
6. A method according to claim 1, 2, 3, 4 or 5 for the delay of progression of a proliferative disease in a subject in need of such treatment.
7. A method according to claim 1, 2, 3, 4 or 5 for the treatment of a proliferative disease associated with a PAX/FKHR translocation, wherein the PAX/FKHR translocation is selected from a PAX3/FKHR translocation and a PAX7/FKHR translocation.
8. Use of a compound of formula I according to claim 1, 2 or 3 for the preparation of a medicament for use in the delay of progression or treatment of a proliferative disease.
9. A method according to claims 6, 7 or 8 wherein the proliferative disease is a sarcoma.
10. A method according to claims 6, 7 or 8 wherein the proliferative disease is associated with a PAX3/FKHR translocation.
11. A method according to claims 6, 7 or 8 wherein the proliferative disease is an Alveolar Rhabdomyosarcoma.
12. A package comprising a compound of formula I in which A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond (or pharmaceutically acceptable salt or prodrug ester thereof), together with instructions for the use in the treatment of a proliferative disease.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/068410

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/553 A61K31/4025 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, FSTA, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/096875 A1 (BURTON GRAHAM [CA] ET AL) 22 May 2003 (2003-05-22) page 1, paragraphs 10,13 - page 2, paragraph 13 page 10, paragraphs 135,136; table 13	1-11
X	WO 97/04761 A (UNIV BOSTON [US]) 13 February 1997 (1997-02-13) page 6, lines 4-9 page 17, lines 4-24; claims 22-24,31	1-11
X	WO 2004/112794 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; COUTRE STEVEN [US]) 29 December 2004 (2004-12-29)	8
Y	the whole document	1-11
	----- -/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 February 2007

Date of mailing of the international search report

28/03/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HOUYVET, C

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/068410

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/037347 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; DANA FARBER CANCER INST I) 8 May 2003 (2003-05-08)	8
Y	the whole document	1-11
X	WO 2005/027971 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; DIMITRIJEVIC SASA [FR]; F) 31 March 2005 (2005-03-31)	8,9
Y	page 1, paragraphs 1,2 page 4, paragraph 2	1-11
A	BERNASCONI M ET AL: "Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 12 NOV 1996, vol. 93, no. 23, 12 November 1996 (1996-11-12), pages 13164-13169, XP002422487 ISSN: 0027-8424 abstract	1-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2006/068410

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-7, 9-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/068410

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2003096875	A1	22-05-2003	NONE	
WO 9704761	A	13-02-1997	AU 6714396 A	26-02-1997
WO 2004112794	A2	29-12-2004	AU 2004248909 A1	29-12-2004
			BR PI0411563 A	01-08-2006
			CA 2527703 A1	29-12-2004
			CN 1805749 A	19-07-2006
			EP 1638574 A2	29-03-2006
			JP 2006527727 T	07-12-2006
			MX PA05013722 A	08-03-2006
WO 03037347	A	08-05-2003	AT 335490 T	15-09-2006
			AU 2006249245 A1	04-01-2007
			BR 0213739 A	19-10-2004
			CA 2462657 A1	08-05-2003
			CN 1582150 A	16-02-2005
			DK 1441737 T3	13-11-2006
			EP 1441737 A1	04-08-2004
			HU 0401642 A2	29-11-2004
			JP 2005507412 T	17-03-2005
			KR 20050040842 A	03-05-2005
			MX PA04004137 A	25-01-2005
			NZ 532136 A	31-08-2006
WO 2005027971	A	31-03-2005	AU 2004273605 A1	31-03-2005
			BR PI0414527 A	07-11-2006
			CA 2538523 A1	31-03-2005
			CN 1852738 A	25-10-2006
			EP 1667719 A1	14-06-2006
			MX PA06003056 A	31-05-2006